A Seismic Shift in the Treatment of Chronic Lymphocytic Leukemia

In reflecting on the narrow range of treatment options available to his first patient, such as chlorambucil and vincristine, and later, combination therapies such as bendamustine-rituximab, Bruce Cheson, MD, characterizes the jump from chemotherapy-based courses to more recent, targeted regimens composed of Bruton's tyrosine kinase (BTK) inhibitors, such as ibrutinib, and monoclonal antibodies, such as obinutuzumab, as a "seismic revolution" — a tectonic shift that allows a wider latitude for patients in terms of treatment approaches, resulting in more positive outcomes.

Medscape © 2022 WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: A Seismic Shift in the Treatment of Chronic Lymphocytic Leukemia - Medscape - Feb 08, 2022.